Compare Duolingo Inc (DUOL) vs Gilead Sciences, Inc. (GILD) Price & Performance

Duolingo (DUOL) trades at $151.22, down 0.33% on the day, as the stock shows mixed technical signals with a bullish moving average trend but neutral oscillators. Fundamentally, the company demonstrates strong growth with revenue reaching $1.04 billion in 2025 and net income of $414 million, representing a robust 35.87% net margin. Recent earnings have consistently beaten expectations, with Q2 2026 EPS of $0.66 exceeding the $0.604 forecast. Analyst sentiment remains divided with a 37.5% buy rating consensus amid ongoing insider selling activity.

The outlook remains cautiously optimistic as Duolingo's AI-driven growth strategy and expanding user base support continued revenue expansion, though valuation multiples appear elevated with a P/E of 17.87 and P/S of 6.47. Key risks include CEO share liquidations, competitive pressures in edtech, and the challenge of sustaining high profit margins. The stock trades near analyst consensus targets, suggesting limited near-term upside potential from current levels.

Gilead Sciences (GILD) trades at $147.10, up 0.17% on the day, with a bullish technical signal and strong analyst consensus. Recent earnings have mostly beaten expectations, though Q2 2026 saw a significant loss. The company maintains robust operating cash flow and has expanded access to its HIV prevention drug lenacapavir in Latin America, signaling growth potential in its core franchises.

The outlook is positive given analyst buy ratings and a $151.57 price target, but risks include negative net income margin and ROE in 2026, high debt levels, and reliance on pipeline success. The stock offers value if HIV and oncology advances materialize, yet investors face volatility from earnings inconsistencies and competitive pressures.